Multi-geography CMO — Pharma & Biotech (primary anchor Australia)

Position overview

Gladwin International Leadership Advisors is representing a confidential organisation in Pharmaceuticals & Biotechnology on a senior CMO leadership mandate anchored in Australia. The remit explicitly spans Middle East, Malaysia, India.

This is a country CEO / MD-class mandate with board- and headquarters-facing accountability for strategy execution, regulatory relationships, and brand in-market.

The mandate fits a leader comfortable owning the narrative externally while upgrading how decisions are made internally.

Context you will inherit

• Market & sector: Biosimilars and specialty pharma commercialisation — moving from commoditised generics to branded specialty requires entirely new commercial leadership capabilities
• Geographic spine: Primary hub Australia with explicit corridor responsibility across Middle East, Malaysia, India.
• Organisation stage: Growth agenda collides with legacy cost base; productivity and automation are board-level topics, not staff functions.
• Stakeholders: Owners may include PE operating partners, a promoter family office, or public-market investors — each with different tempo and KPIs.
• Secondary lens: R&D and innovation leadership — transitioning from generic-follow business models to differentiated, IP-rich innovation pipelines requires a different type of scientific and commercial leadership

The mandate (12–24 month arc)

1. Growth playbook: Define repeatable plays for new logo acquisition, cross-sell, and retention in priority verticals.
2. Content & thought leadership: Elevate executive visibility in forums that matter to buyers and regulators (where relevant).
3. Pricing & packaging: Partner with sales and product on packaging that reflects value, not internal cost structures.
4. Marketing organisation: Structure team around journeys and segments — reduce silos between brand, demand, and comms.
5. Crisis & reputation: Build protocols and narratives for high-stakes communications scenarios.
6. Measurement: Tie marketing KPIs to revenue proxies the CFO and CEO will accept.

Responsibilities (representative)

• Build product marketing capability tied to roadmap and revenue plays.
• Improve marketing ROI measurement — acceptable proxies where full attribution is impossible.
• Develop partner and channel marketing where indirect routes dominate.
• Instil crisis communications readiness with legal and corporate affairs.
• Coach the organisation on narrative discipline — one story, many channels.

Leadership profile

• Education: Strong undergraduate grounding; MBA / advanced degree / professional qualification common at this level.
• Modern marketing: Fluency with data, segmentation, and accountable spend — not only creative excellence.
• Judgment: High signal-to-noise under pressure; ethical clarity; willingness to halt initiatives that break risk appetite.
• Communication: Executive presence in English; additional languages valued where market-relevant.
• Geographic muscle: Comfort operating from Australia with regular engagement across Middle East, Malaysia.

Team & culture

Expect some fatigue from prior change programmes. Your success depends on simpler priorities, fewer initiatives, and leaders who model accountability. Culture is how decisions get made when spreadsheets disagree — you set that tone.

Success measures (examples)

• Growth quality: Mix of recurring revenue, new logos, and cross-sell — not volume for its own sake.
• Productivity: Unit cost, automation savings, or throughput improvements with audited baselines.
• Customer: NPS / CSAT where tracked; contract renewals; reference-ability in strategic accounts.
• Franchise: Clean compliance record; reputation stability in industry and government forums.

First 90 days (orientation arc)

• Days 1–30: Listening tour — customers, regulators (as appropriate), top team 1:1s, and unfiltered view of numbers; pause major reorganisation.
• Days 30–60: Publish a short memo on priorities, non-goals, and decision rights; align executive committee on three enterprise bets.
• Days 60–90: Lock operating cadence; fill or upgrade one to two critical seats; deliver one visible win (customer, cost, or culture).
• Commission a pragmatic view of data, cyber, and automation posture; sponsor one bounded pilot with ROI hypothesis.
• Establish escalation discipline with matrix partners — fewer meetings, clearer decision logs.

Stakeholder map (illustrative)

• Internal: CEO or regional president, CFO, risk / legal, CHRO, CIO or CDO, business GMs, internal audit.
• External: Strategic accounts, channel partners, industry associations, regulators (where material).
• Owners: PE operating partners, promoter office, or public investors — pace and clarity matter as much as vision.

Travel & mobility

Travel weighted to priority markets and quarterly global or regional forums; flexibility for crisis windows.

Compensation

Market-aligned CMO remuneration in Pharmaceuticals & Biotechnology with performance linkage; sign-on and relocation considered for exceptional fits.

Application status

This mandate is no longer accepting new applications. The search progressed through Q4 2025 and closed for submissions in February 2026. We retain this posting for transparency on the type of leadership work we carry in Pharmaceuticals & Biotechnology and Australia. For similar active mandates, browse open roles or submit a general profile through executive search inquiry.

Reference: pharmaceuticals-biotech · CMO · Australia · Gladwin International Leadership Advisors